Monopar Therapeutics (MNPR) Competitors $37.20 +0.95 (+2.62%) Closing price 07/7/2025 04:00 PM EasternExtended Trading$36.38 -0.83 (-2.22%) As of 07:06 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MNPR vs. AVXL, COGT, CMRX, CDMO, AVBP, SNDX, IMNM, QURE, PHAR, and XERSShould you be buying Monopar Therapeutics stock or one of its competitors? The main competitors of Monopar Therapeutics include Anavex Life Sciences (AVXL), Cogent Biosciences (COGT), Chimerix (CMRX), Avid Bioservices (CDMO), ArriVent BioPharma (AVBP), Syndax Pharmaceuticals (SNDX), Immunome (IMNM), uniQure (QURE), Pharming Group (PHAR), and Xeris Biopharma (XERS). These companies are all part of the "pharmaceutical products" industry. Monopar Therapeutics vs. Its Competitors Anavex Life Sciences Cogent Biosciences Chimerix Avid Bioservices ArriVent BioPharma Syndax Pharmaceuticals Immunome uniQure Pharming Group Xeris Biopharma Monopar Therapeutics (NASDAQ:MNPR) and Anavex Life Sciences (NASDAQ:AVXL) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation, dividends and media sentiment. Does the media prefer MNPR or AVXL? In the previous week, Anavex Life Sciences had 1 more articles in the media than Monopar Therapeutics. MarketBeat recorded 4 mentions for Anavex Life Sciences and 3 mentions for Monopar Therapeutics. Monopar Therapeutics' average media sentiment score of 0.50 beat Anavex Life Sciences' score of 0.45 indicating that Monopar Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monopar Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Anavex Life Sciences 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has better earnings & valuation, MNPR or AVXL? Anavex Life Sciences is trading at a lower price-to-earnings ratio than Monopar Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMonopar TherapeuticsN/AN/A-$15.59M-$3.48-10.69Anavex Life SciencesN/AN/A-$43M-$0.55-18.16 Which has more volatility & risk, MNPR or AVXL? Monopar Therapeutics has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500. Comparatively, Anavex Life Sciences has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500. Do institutionals and insiders hold more shares of MNPR or AVXL? 1.8% of Monopar Therapeutics shares are held by institutional investors. Comparatively, 31.6% of Anavex Life Sciences shares are held by institutional investors. 20.5% of Monopar Therapeutics shares are held by insiders. Comparatively, 11.0% of Anavex Life Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Is MNPR or AVXL more profitable? Anavex Life Sciences' return on equity of -40.93% beat Monopar Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Monopar TherapeuticsN/A -55.39% -51.53% Anavex Life Sciences N/A -40.93%-36.38% Do analysts recommend MNPR or AVXL? Monopar Therapeutics currently has a consensus price target of $60.00, indicating a potential upside of 61.29%. Anavex Life Sciences has a consensus price target of $44.00, indicating a potential upside of 340.44%. Given Anavex Life Sciences' stronger consensus rating and higher probable upside, analysts plainly believe Anavex Life Sciences is more favorable than Monopar Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Monopar Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Anavex Life Sciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 SummaryAnavex Life Sciences beats Monopar Therapeutics on 8 of the 14 factors compared between the two stocks. Get Monopar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MNPR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MNPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MNPR vs. The Competition Export to ExcelMetricMonopar TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$221.68M$2.91B$5.52B$9.02BDividend YieldN/A2.44%5.24%4.05%P/E Ratio-10.6920.4427.2220.08Price / SalesN/A190.25381.5993.26Price / CashN/A41.7026.2128.59Price / Book4.127.397.945.55Net Income-$15.59M-$55.04M$3.17B$248.49M7 Day Performance10.85%2.51%1.79%4.87%1 Month Performance0.24%-0.21%1.27%6.63%1 Year Performance908.27%3.41%33.57%20.38% Monopar Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MNPRMonopar Therapeutics2.9752 of 5 stars$37.20+2.6%$60.00+61.3%+933.2%$221.68MN/A-10.6910News CoverageAnalyst ForecastAVXLAnavex Life Sciences3.5734 of 5 stars$9.22-2.7%$44.00+377.2%+138.4%$809.33MN/A-16.7640Positive NewsCOGTCogent Biosciences2.6058 of 5 stars$7.18+1.1%$14.43+101.0%+10.8%$808.38MN/A-3.9080Trending NewsAnalyst ForecastOptions VolumeGap UpCMRXChimerix0.6241 of 5 stars$8.54flat$8.53-0.1%N/A$801.09M$212K-9.0990CDMOAvid Bioservices0.6877 of 5 stars$12.50+0.1%$12.25-2.0%+68.4%$799.18M$139.91M-5.23320High Trading VolumeAVBPArriVent BioPharma1.7398 of 5 stars$21.77-5.0%$40.00+83.7%+8.4%$783.81MN/A-5.7740SNDXSyndax Pharmaceuticals3.1324 of 5 stars$9.36+3.5%$35.80+282.5%-58.3%$777.87M$23.68M-2.42110IMNMImmunome2.4292 of 5 stars$9.30+6.0%$23.33+150.9%-27.8%$763.10M$9.04M-2.9240High Trading VolumeQUREuniQure2.1019 of 5 stars$13.94+0.6%$37.82+171.3%+272.7%$759.19M$27.12M-3.18500PHARPharming Group2.733 of 5 stars$10.68-2.9%$30.00+181.0%+28.8%$748.58M$297.20M-53.38280Positive NewsGap DownHigh Trading VolumeXERSXeris Biopharma3.5893 of 5 stars$4.67-0.6%$6.25+33.8%+122.7%$735.01M$222.55M-15.57290Positive News Related Companies and Tools Related Companies Anavex Life Sciences Alternatives Cogent Biosciences Alternatives Chimerix Alternatives Avid Bioservices Alternatives ArriVent BioPharma Alternatives Syndax Pharmaceuticals Alternatives Immunome Alternatives uniQure Alternatives Pharming Group Alternatives Xeris Biopharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MNPR) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monopar Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Monopar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MNPR Stock Alerts